Literature DB >> 22233815

Thalidomide: an old drug with new action.

V Kumar1, S Chhibber.   

Abstract

Thalidomide is a drug that, since its development, has made history in the world of medicine--having been withdrawn and now has returned with a boom as an anticancer and immunomodulatory drug. However, its mode of action in various diseases (i.e. different types of hematologic malignancies, solid tumors) as well as in various infections (i.e. pneumonia, tuberculosis, HIV infection etc.) and related inflammatory conditions is not well understood. As the immune system plays an important role in the pathogenesis of both infection-related as well as noninfectious (i.e. cancer) inflammatory diseases, much research has been done in the past few years to discover and design better immunomodulatory agents. Such immunomodulatory agents should be able to target the immune system in such a way that host suffers minimum damage and normal function of the immune system remains intact. In the present review an attempt is made to highlight the immunomodulatory action of thalidomide in various pathologic conditions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22233815     DOI: 10.1179/joc.2011.23.6.326

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  11 in total

1.  Thalidomide Inhibits Angiogenesis via Downregulation of VEGF and Angiopoietin-2 in Crohn's Disease.

Authors:  Lin Wang; Shengnan Wang; Aijuan Xue; Jieru Shi; Cuifang Zheng; Ying Huang
Journal:  Inflammation       Date:  2020-11-18       Impact factor: 4.092

Review 2.  Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation.

Authors:  Raimondo D'Ambrosio; Clifford L Eastman; Cinzia Fattore; Emilio Perucca
Journal:  Expert Rev Neurother       Date:  2013-06       Impact factor: 4.618

3.  Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice.

Authors:  Haiyan Zhu; Xunlong Shi; Dianwen Ju; Hai Huang; Wei Wei; Xiaoying Dong
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

Review 4.  Thalidomide-a notorious sedative to a wonder anticancer drug.

Authors:  Shuang Zhou; Fengfei Wang; Tze-Chen Hsieh; Joseph M Wu; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 5.  Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.

Authors:  Ruirong Chen; Zhien Lan; Jujian Ye; Limin Pang; Yi Liu; Wei Wu; Xiaohuan Qin; Yang Guo; Peidong Zhang
Journal:  Front Immunol       Date:  2021-04-28       Impact factor: 7.561

6.  Environmental factors in autism.

Authors:  Andreas M Grabrucker
Journal:  Front Psychiatry       Date:  2013-01-18       Impact factor: 4.157

Review 7.  Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.

Authors:  Ahmed M Al-Abd; Abdulmohsin J Alamoudi; Ashraf B Abdel-Naim; Thikryat A Neamatallah; Osama M Ashour
Journal:  J Adv Res       Date:  2017-06-27       Impact factor: 10.479

8.  Thalidomide in the Treatment of Sweet's Syndrome and Eosinophilic Folliculitis Associated With Immune Reconstitution Inflammatory Syndrome.

Authors:  Rong-Jing Dong; Shi-Zhen Huang; Pratishtha Upadhyay; Samip Shrestha; Ya-Jie Zhai; Yu-Ye Li
Journal:  Front Med (Lausanne)       Date:  2020-01-21

9.  The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.

Authors:  Tina Dasgupta; Daphne A Haas-Kogan
Journal:  Front Oncol       Date:  2013-05-10       Impact factor: 6.244

10.  Thalidomide Accelerates the Degradation of Extracellular Matrix in Rat Hepatic Cirrhosis via Down-Regulation of Transforming Growth Factor-β1.

Authors:  Peng Lv; Qingshun Meng; Jie Liu; Chuanfang Wang
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.